Form 4: Brainstorm Cell Therapeutics Executive Receives Stock Award Following Reverse Stock Split

Hartoun Hartounian, EVP and COO of Brainstorm Cell Therapeutics, received 50,000 shares of restricted stock on January 1, 2025, following a 1-for-15 reverse stock split.

Summary

• Hartoun Hartounian, the EVP and Chief Operating Officer of Brainstorm Cell Therapeutics, received 50,000 shares of restricted stock on January 1, 2025.
• These shares were awarded under the company's 2014 Stock Incentive Plan.
• The shares vest in two tranches: 50% after six months and the remaining 50% after eighteen months, contingent on continued employment.
• The reported holdings also reflect a 1-for-15 reverse stock split that occurred on October 1, 2024.

Sentiment

Score: 7

Explanation: The document reflects standard corporate actions and executive compensation, which is generally neutral to positive. The stock award is a positive incentive for the executive.

Positives

• The stock award serves as an incentive for the executive to remain with the company.
• The vesting schedule aligns the executive's interests with the long-term performance of the company.

Risks

• The vesting of the shares is contingent on continued employment, which could be a risk if the executive leaves the company before the vesting dates.

Industry Context

This filing is a routine disclosure of executive compensation and stock ownership changes, which is common in publicly traded companies. The reverse stock split is a corporate action often taken to increase the share price and maintain listing requirements.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotechnology industry to attract and retain key talent.
• Reverse stock splits are often used by companies with low share prices to avoid delisting from exchanges, which is not uncommon in the biotech sector.
• The vesting schedule of the restricted stock is typical, with vesting periods ranging from a few months to several years.

Stakeholder Impact

• The stock award could be viewed positively by shareholders as it aligns executive interests with company performance.
• The reverse stock split may have a neutral impact on shareholders, as it does not change the overall value of their holdings.

Key Dates

Keywords

stock award, restricted stock, executive compensation, reverse stock split, insider trading, Brainstorm Cell Therapeutics, BCLI